StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

UroGen Pharma's price to sales ratio was 6.8× on Nov 11, 2026, against 14.0× a year earlier. Over the last 5 years it ranged from 2.1× to 14.0×, with a median of 5.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.8×−4.6
2025Dec 31, 202511.4×+6.3
2024Dec 31, 20245.0×−3.2
2023Dec 29, 20238.2×+4.9
2022Dec 30, 20223.3×−2.1
2021Dec 31, 20215.3×−453.0
2019Jan 31, 2019458.4×−18.2
2018Dec 31, 2018476.5×+471.6
2017Dec 29, 20174.9×–

More UroGen Pharma figures

See a number that looks wrong?